Ducommun Incorporated posted record third quarter 2026 results with net revenue of $227 million, a 6% increase year-over-year, and a gross margin of 28.9%, up 140 basis points. Net income reached $13.9 million, reversing a prior year loss, driven by growth in commercial aerospace and strong defense bookings with a book-to-bill ratio of 2.2x. The company highlighted progress toward its VISION 2027 financial goals and introduced its VISION 2032 plan targeting $1.6-$1.7 billion in annual revenue and 23% adjusted EBITDA margin. Strong order backlog and operational improvements position Ducommun for sustained multi-year growth.
Ducommun Incorporated's third quarter 2026 results provide context for readers interested in industrial sector trends. For readers following Industrials, here is Pluang's market snapshot as of Nov 05, 2026 17:21 WIB: Of 135 priced Industrials-sector US stocks tradable on Pluang, 65 rose and 67 fell today. Expeditors International of Wshngtn Inc (EXPD) gained 3.52% with 100% buy orders and a typical hold time of 46 days, contrasting with Bloom Energy (BE) which dropped 3.69% and had a 58% buy order ratio over 15 days. Thomson Reuters Corp (TRI) also declined 3.56% with a longer hold time of 64 days and 73% sell orders.
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
Dune has completed a SOC 2 Type II examination with no exceptions, providing institutional clients with verified assurance of its data security standards. This milestone comes as tokenized real-world assets doubled to $32.6 billion and stablecoin mar...
Northern Discovery Metals has finalized the acquisition of a 100% interest in the Cibola copper-gold project in British Columbia from Orogen Royalties. The project covers about 3,567 hectares near Houston, BC, in a region known for porphyry copper de...
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
